ClinicalTrials.gov record

Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

ClinicalTrials.gov ID: NCT01198509

Public ClinicalTrials.gov record NCT01198509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity. Even though there have been many advances in the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors still do not know what causes this inflammation in joints. It is likely that RA occurs as a result of a complex combination of factors, including a person's genes; lifestyle choices, such as smoking and diet; and things in a person's environment, including bacteria or viruses. This study investigates the hypothesis that bacteria living in a person's mouth and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid Arthritis. The investigators believe that by killing those bacteria with antibiotics, they might be able to understand how the immune system works and, maybe, what causes RA.

Study identification

NCT ID: NCT01198509
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: NYU Langone Health; Other
Enrollment: 178 participants

Conditions and interventions

Conditions

Interventions

doxycycline Drug
vancomycin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2009
Primary completion: Dec 31, 2012
Completion: Dec 31, 2012
Last update posted: Jan 12, 2015

2010 – 2013

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
NYU Hospital for Joint Diseases	New York	New York	10003	—
Bellevue Hospital	New York	New York	10016	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01198509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 12, 2015 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01198509 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →